To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have AML that has returned or stopped responding to at least one prior regimen of chemotherapy.
- At least 2 weeks must have passed since completion of prior treatment and entry into the study.
- Patients must be able to be ambulatory for more than half of their normal waking hours.
- This study is open to patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Martin Tallman at 212-639-3842.